Recurrent ER+ tumors are insensitive to endocrine therapy, similar to TNBC, suggesting that endocrine therapy-resistant ER+ breast cancer may be functionally similar to TNBC, with potentially overlapping risk factors and drivers. This evidence concerns the gene ESR1 and breast carcinoma.